What are the main findings and differences among the CRASH‑1, CRASH‑2, and CRASH‑3 trials regarding the use of tranexamic acid and corticosteroids in bleeding trauma patients and those with isolated traumatic brain injury?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

CRASH Trials: Key Findings and Differences

The CRASH trials represent landmark studies on tranexamic acid (TXA) in trauma: CRASH-2 demonstrated mortality reduction in bleeding trauma patients when given within 3 hours, CRASH-3 showed benefit specifically in mild-to-moderate traumatic brain injury (TBI) when treated early, while CRASH-1 examined corticosteroids in head injury and found no benefit (leading to recommendations against steroid use in major trauma). 1, 2, 3

CRASH-2 Trial: TXA in Bleeding Trauma

Primary Focus: Extracranial hemorrhage in trauma patients

Key Findings:

  • Reduced overall mortality by 1.5% and bleeding deaths by one-third when administered appropriately 1
  • Critical time window: Treatment within 3 hours of injury reduces bleeding deaths, but treatment after 3 hours actually increases mortality risk 4
  • The time-dependent effect is not explained by injury type, blood pressure, or presence of head injury—it's purely about timing 4
  • Established the standard TXA dosing: 1g bolus over 10 minutes, followed by 1g infusion over 8 hours 1

Clinical Application:

  • Should be given to any bleeding trauma patient or those at risk of significant bleeding
  • Must be administered as soon as possible, ideally en route to hospital
  • Do not wait for viscoelastic assessment results before giving TXA 1

CRASH-3 Trial: TXA in Traumatic Brain Injury

Primary Focus: Isolated TBI with intracranial bleeding (n=12,737 patients, with 9,202 treated within 3 hours) 3

Key Findings:

  • Benefit limited to mild-to-moderate TBI: Risk ratio 0.78 (95% CI 0.64-0.95) for head injury-related death 3
  • No benefit in severe TBI (GCS 3-8): Risk ratio 0.99 (95% CI 0.91-1.07) 3
  • When excluding moribund patients (GCS=3 or bilateral unreactive pupils), the benefit became clearer: 12.5% mortality with TXA vs 14.0% with placebo 3
  • Early treatment is critical: The benefit was strongest within 2 hours and diminished rapidly thereafter, though patients with severe TBI (GCS <9) may benefit beyond 3 hours 5
  • TXA reduced early deaths (within 24 hours) by 26% in non-moribund TBI patients (RR 0.74,95% CI 0.58-0.94) 6

Safety Profile:

  • No increase in vascular occlusive events (RR 0.98) or seizures (RR 1.09) 3
  • However, prolonged use beyond 1 day or delayed administration beyond 8 hours increases thromboembolic risk 7

CRASH-1: Corticosteroids in Head Injury

Primary Focus: Corticosteroid use in major trauma and TBI

Key Findings:

  • No mortality benefit: Risk ratio 1.00 (95% CI 0.89-1.13) across 19 trials with 12,269 patients 2
  • No dose-dependent effect observed (low vs high dose corticosteroids showed similar lack of benefit) 2
  • No increase in gastrointestinal bleeding or superinfection, but potential for clinically important side effects 2

Current Recommendation:

  • Corticosteroids are NOT recommended for major trauma (conditional recommendation, low quality evidence) 2
  • This contrasts with their use in ARDS, where methylprednisolone has a role 2

Critical Clinical Distinctions

Time Windows:

  • CRASH-2 and CRASH-3 both emphasize treatment within 3 hours, with optimal benefit within 2 hours 1, 5
  • Treatment after 3 hours may cause harm in bleeding trauma 4
  • Severe TBI patients (GCS <9) may benefit beyond the 2-hour window 5

Patient Selection:

  • Bleeding trauma (CRASH-2): Any significant extracranial hemorrhage
  • TBI (CRASH-3): Mild-to-moderate head injury (GCS 9-15 or GCS <9 if pupils reactive)
  • Avoid in moribund patients: Those with GCS=3 and bilateral unreactive pupils show no benefit 3, 6

Contraindications from FDA labeling:

  • Absolute contraindication in subarachnoid hemorrhage due to cerebral edema and infarction risk 8
  • Active intravascular clotting 8
  • Severe hypersensitivity reactions 8

Practical Algorithm

For bleeding trauma patients:

  1. Administer TXA immediately if within 3 hours of injury
  2. Use standard dosing: 1g bolus + 1g infusion over 8 hours
  3. Do not delay for laboratory results

For isolated TBI patients:

  1. Assess GCS and pupillary reactivity
  2. If GCS 9-15 or GCS <9 with reactive pupils AND within 3 hours: give TXA
  3. If GCS=3 with bilateral unreactive pupils: withhold TXA (no benefit)
  4. Prioritize treatment within 2 hours when possible

Avoid:

  • TXA administration beyond 3 hours in bleeding trauma (may increase mortality)
  • Prolonged TXA use beyond 24 hours (increases thromboembolic risk)
  • Corticosteroids in trauma (no benefit, potential harm)

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.